

Technology Advisory Committee D Interests Register

Topic [ID6170]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Will Sullivan	Committee Member	Direct - Financial	<p>Will is an employee of a consultancy company that provides paid services to various pharmaceutical companies. Will has provided consultancy work through his employment for one potential competitor company for this appraisal, Hoffman-La Roche, in the last 12 months.</p> <p>The work concerned a technology and indication different to those under consideration for this topic.</p>	12/03/2024	It was agreed that Will's declaration would not prevent him from participating in discussions on this appraisal.
Dr Charles Hay	Clinical Expert	Direct - Financial	<ul style="list-style-type: none"> Dr Hay received Sobi Sponsorship to attend the Congress of the International Society of Thrombosis and Haemostasis in Montreal, June 2023. He has participated in past advisory panel discussions with Sobi, Roche and CSL. These are not ongoing. 	03/10/2023	It was agreed that Dr Hay's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> Dr Hay has received past speaker honoraria from Roche and CSL. He has no pharmaceutical shareholdings. Sobi paid Dr Hay a one-off consultancy fee for advice and opinion on likely uptake and placement of efanesoctocog alfa in the UK in general. 		
Dr Charles Hay	Clinical Expert	Direct Non-financial	As Director of the NHD, Dr Hay signs off on reports for NHS England, Scotland and Wales, and Roche, CSL, Sobi, Pfizer but he derives no personal financial benefit from this.	03/10/2023	It was agreed that Dr Hay's declaration would not prevent him from providing expert advice to the committee.
Edward Rippingale-Combes	Patient Expert	Direct – financial	Edward is in paid employment as a clinical research nurse in the NHS. He works on commercial and non-commercial research in the trauma, critical care, cardiology, diabetes, and ophthalmology specialist areas within a district general NHS hospital. Edward previously worked in Dermatology research.	20/09/2023	It was agreed that Edward's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Edward Rippingale-Combes	Patient Expert	Direct – non-financial	Edward is a current research participant in a trial of efanesoctocog	20/09/2023	It was agreed that Edward's declaration would not prevent him from providing expert advice to the committee.
Clive Smith	Patient Expert	Direct - financial	<ul style="list-style-type: none"> Clive has received payments from both Sanofi and SOBI over the last 12 months. Clive has worked with Sanofi on 2 projects, one of which he received remuneration for. This was as a keynote speaker for the "Haemophilia Changemakers 2023 Series" called "Catalyze and sustain long-term impact: Developing calls-to-action that drive fundamental change in the next generation". Clive has worked with SOBI on several projects over the last 12 months – one on an advisory board during the course of the year and another as the chair and speaker of an event at the European 	20/09/2023	It was agreed that Clive's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Haemophilia Consortium Conference in Zagreb in October 2023.</p> <ul style="list-style-type: none">• Clive has recently reviewed a plain language summary of an article adapted for patients from a NEJM article on this product. He will be remunerated for his time doing this.		